Clovis Oncology Inc., of Boulder, Colo., said the underwriters of its initial public offering exercised their option to purchase an additional 700,000 shares of Clovis common stock to cover overallotments. J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering, with Leerink Swann LLC acting as co-manager.